I don't know why Vertex or CRISPR chose to PR this... perhaps there was additional relevant updates that came with PRing that information. Maybe those companies think updating the public that an administrative task like check marking off that all the modules are properly complete is worthy of PRing. Perhaps those companies aren't under the same type of microscope Northwest is and they can get away with writing moderately meaningless PRs.
And I agree... the status of an approval is what is important and what we are now waiting on. :)
The rumor is that Vertex/CRISPR’s initial application for exa-cel was rejected by the MHRA, and they were required to refile, so it was appropriate in that case to make a second press release that the application was validated and accepted.
This may have prompted the MHRA to become more proactive with applicants after the pre-submission meeting, to ensure that applications are higher quality.
News 
Market Data 
Discover 
